Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–165 of 165 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: LIRAGLUTIDE Clear all

Conditions: Obesity
Interventions: Semaglutide, Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Liraglutide, Golimumab; Drug
Lead sponsor: Carla Greenbaum, MD; Other
Eligibility: 18 Years to 50 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Idaho Falls, Idaho • Seattle, Washington

Conditions: Obesity in Children, Bone Strength, GLP - 1, Lifestyle Modification, Bone Density, Obesity
Interventions: GLP-1 receptor agonist, Lifestyle intervention; Drug · Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 12 Years to 21 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Type 2 Diabetes Mellitus
Interventions: 50 mg PB1023, 70 mg PB1023, 100 mg PB1023, Placebo (0.9% Sodium Chloride), Victoza®, Diet and Exercise, Metformin, Sulfonylurea, Metformin and Sulfonylurea; Drug · Other
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 593 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 93
States / cities: Anniston, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 90 more

Conditions: Obesity
Interventions: CMS-recommended lifestyle counseling, Liraglutide 3.0mg, Portion-Controlled Diet, Placebo Oral Tablet, Phentermine 15 MG, Extension Study CMS-recommended lifestyle counseling; Behavioral · Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obesity
Interventions: Liraglutide, Placebo; Drug
Lead sponsor: Michael Camilleri, MD; Other
Eligibility: 18 Years to 65 Years
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Obesity
Interventions: Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion, Phentermine; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Type 2 Diabetes
Interventions: HM11260C, liraglutide, Placebo; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: CA, California

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec/liraglutide, insulin glargine; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 557 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 31
States / cities: Fresno, California • Los Alamitos, California • Palm Springs, California + 26 more

Conditions: Obesity
Interventions: Incretin-based therapies (GLP-1 and GLP-1/GIP); Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 125,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Diabetes Mellitus, Type 2, Obesity, Gastroparesis
Interventions: GLP-1 medication; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: Not listed
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Weston, Florida • Cleveland, Ohio

Conditions: Obesity
Interventions: Semaglutide, Phentermine-Topiramate combination, Phentermine, Tirzepatide, Topiramate, Diethylpropion, Naltrexone/Bupropion, Liraglutide; Drug
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 35 Years to 60 Years
Enrollment: 30 participants
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: New Orleans, Louisiana

Conditions: Type 1 Diabetes
Interventions: Victoza, Placebo, Dapagliflozin 10mg Tab; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 75 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Diabetes, Effects of Liraglutide Administration on Brain Activity, Weight Loss, Hunger
Interventions: Liraglutide, Placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity
Interventions: liraglutide, Placebo; Drug · Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Smoking Cessation, Weight, Body
Interventions: Liraglutide, Placebo, Smoking Cessation Counseling; Drug · Behavioral
Lead sponsor: Rebecca Ashare; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obesity, Overweight
Interventions: Tirzepatide, Placebo, Liraglutide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Indianapolis, Indiana • Baton Rouge, Louisiana • Baltimore, Maryland

Conditions: Pouchitis, Irritable Pouch Syndrome
Interventions: Liraglutide Pen Injector, Placebo Pen Injector; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Knee Osteoarthritis, Synovitis of Knee
Interventions: 4P004, Placebo (NaCl 0.9%); Drug
Lead sponsor: 4Moving Biotech; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Tucson, Arizona • Chicago, Illinois • Burlington, Massachusetts

Conditions: Obesity
Interventions: GSK2890457, Metformin, Placebo, Liraglutide; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 3
States / cities: Chula Vista, California • Miami, Florida • Overland Park, Kansas

Conditions: Type 2 Diabetes, Gastric Banding
Interventions: Liraglutide, Orlistat, Liraglutide + Orlistat; Drug
Lead sponsor: East Carolina University; Other
Eligibility: 25 Years to 70 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Greenville, North Carolina

Search by objective public record fields.

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D

Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

Lifestyle Modification and Liraglutide

Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity

Individualized Obesity Pharmacotherapy

Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus

Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes

Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy

Anti-obesity Pharmacotherapy and Inflammation

Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes

Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI

Saxenda: Underlying Mechanisms and Clinical Outcomes

Daily Liraglutide for Nicotine Dependence

A Study of Tirzepatide in Overweight and Very Overweight Participants

Efficacy of Liraglutide Therapy in Patients With IPAA

A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis

To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes

Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding